Substituted 5-fluoro-1H-pyrazolopyridines and their use
The present application relates to novel substituted 5-fluoro-1H-pyrazolopyridines, to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.
1. A method of treating or preventing one or more of coronary heart disease, systolic or diastolic heart failure, angina pectoris, ischaemias, peripheral and cardiac vascular disorders, kidney failure, renal insufficiency, and increased microalbuminurea, comprising administering a therapeutically effective amount of a compound of formula (I-A)
or a salt thereof to a human or animal in need thereof.
2. The method of claim 1 , comprising administering a therapeutically effective amount of the compound of formula (I-A)
3. The method of claim 1 , comprising administering a therapeutically effective amount of the salt of the compound of formula (I-A)
4. The method of claim 1 , wherein the method is for treating angina pectoris.
5. The method of claim 2 , wherein the method is for treating angina pectoris.
6. The method of claim 3 , wherein the method is for treating angina pectoris.
7. The method of claim 1 , wherein the method is for treating vascular disorders.
8. The method of claim 2 , wherein the method is for treating vascular disorders.
9. The method of claim 3 , wherein the method is for treating vascular disorders.
10. The method of claim 1 , wherein the method is for treating kidney failure.
11. The method of claim 2 , wherein the method is for treating kidney failure.
12. The method of claim 3 , wherein the method is for treating kidney failure.
13. The method of claim 1 , wherein the method further comprises administering a further active compound that is a cGMP-PDE inhibitor selected from the group consisting of sildenafil, vardenafil and tadalafil.
14. The method of claim 2 , wherein the method further comprises administering a further active compound that is a cGMP-PDE inhibitor selected from the group consisting of sildenafil, vardenafil and tadalafil.
15. The method of claim 3 , wherein the method further comprises administering a further active compound that is a cGMP-PDE inhibitor selected from the group consisting of sildenafil, vardenafil and tadalafil.
16. The method of claim 1 , wherein the method further comprises administering a further active compound that is an agent having blood pressure lowering activity selected from the group consisting of losartan, candesartan, valsartan, telmisartan, embusartan, bosentan, darusentan, ambrisentan, sitaxsentan, and spironolactone and eplerenone.
17. The method of claim 2 , wherein the method further comprises administering a further active compound that is an agent having blood pressure lowering activity selected from the group consisting of losartan, candesartan, valsartan, telmisartan, embusartan, bosentan, darusentan, ambrisentan, sitaxsentan, and spironolactone and eplerenone.
18. The method of claim 3 , wherein the method further comprises administering a further active compound that is an agent having blood pressure lowering activity selected from the group consisting of losartan, candesartan, valsartan, telmisartan, embusartan, bosentan, darusentan, ambrisentan, sitaxsentan, and spironolactone and eplerenone.
19. The method of claim 1 , wherein the method is for treating coronary heart disease.
20. The method of claim 2 , wherein the method is for treating coronary heart disease.
21. The method of claim 3 , wherein the method is for treating coronary heart disease.
22. The method of claim 1 , wherein the method is for treating systolic or diastolic heart failure.
23. The method of claim 2 , wherein the method is for treating systolic or diastolic heart failure.
24. The method of claim 3 , wherein the method is for treating systolic or diastolic heart failure.
25. The method of claim 1 , wherein the method is for treating renal insufficiency.
26. The method of claim 2 , wherein the method is for treating renal insufficiency.
27. The method of claim 3 , wherein the method is for treating renal insufficiency.
28. The method of claim 1 , wherein the method is for treating increased microalbuminurea.
29. The method of claim 2 , wherein the method is for treating increased microalbuminurea.
30. The method of claim 3 , wherein the method is for treating increased microalbuminurea.
31. A method of treatment of heart failure, hypertension, or pulmonary hypertension in humans and animals comprising administering an effective amount of a compound of formula (I-A)
or a salt thereof to a human or animal in need thereof.
32. The method of claim 31 , wherein the method is for treatment of heart failure.
33. The method of claim 31 , wherein the method is for treatment of hypertension.
34. The method of claim 31 , wherein the method is for treatment of pulmonary hypertension.
35. The method of claim 31 , wherein an effective amount of the salt of the compound of formula (I-A) is administered.
36. The method of claim 32 , wherein an effective amount of the salt of the compound of formula (I-A) is administered.
37. The method of claim 33 , wherein an effective amount of the salt of the compound of formula (I-A) is administered.
38. The method of claim 34 , wherein an effective amount of the salt of the compound of formula (I-A) is administered.
39. A method of treating or preventing one or more of hypertension, pulmonary hypertension, heart failure, coronary heart disease, systolic or diastolic heart failure, angina pectoris, ischaemias, peripheral and cardiac vascular disorders, kidney failure, renal insufficiency, and increased microalbuminurea, comprising administering to a human or animal in need thereof therapeutically effective amounts of
(1) a compound of formula (I-A)
or a salt thereof; and
(2) a further active compound selected from the group consisting of organic nitrates, NO donors, cGMP-PDE inhibitors, agents having antithrombotic activity, agents lowering blood pressure, and agents altering lipid metabolism.
40. The method of claim 39 , wherein an effective amount of the compound of formula (I-A) is administered.
41. The method of claim 39 , wherein an effective amount of the salt of the compound of formula (I-A) is administered.
42. The method of claim 39 , wherein the further active compound is selected from the group consisting of sodium nitroprusside, nitroglycerin, isosorbide mononitrate, isosorbide dinitrate, molsidomine or SIN-1, inhaled NO, inhibitors of phosphodiesterases (PDE) 1, 2 and/or 5, platelet aggregation inhibitors, anticoagulants, profibrinolytic substances, calcium antagonists, angiotensin AII antagonists, ACE inhibitors, endothelin antagonists, renin inhibitors, alpha-receptor blockers, beta-receptor blockers, mineralocorticoid receptor antagonists, diuretics, thyroid receptor agonists, HMG-CoA reductase inhibitors, squalene synthesis inhibitors, ACAT inhibitors, CETP inhibitors, MTP inhibitors; PPAR-alpha, PPAR-gamma and/or PPAR-delta agonists, cholesterol absorption inhibitors, lipase inhibitors, polymeric bile acid adsorbents, bile acid reabsorption inhibitors and lipoprotein(a) antagonists.
43. The method of claim 42 , wherein the inhibitor of phosphodiesterases (PDE) 1, 2 and/or 5 is selected from the group consisting of sildenafil, vardenafil, and tadalafil.
44. The method of claim 42 , wherein the angiotensin AII antagonist is selected from the group consisting of losartan, candesartan, valsartan, telmisartan, and embusartan.
45. The method of claim 42 , wherein the endothelin antagonist is selected from the group consisting of bosentan, darusentan, ambrisentan, and sitaxsentan.
46. The method of claim 42 , wherein the mineralocorticoid receptor antagonist is selected from the group consisting of spironolactone or eplerenone.
47. The method of claim 42 , wherein an effective amount of the compound of formula (I-A) is administered.
48. The method of claim 42 , wherein an effective amount of the salt of the compound of formula (I-A) is administered.
49. A method of treating or preventing one or more of vascular disorders, thromboembolic disorders, fibrotic disorders, and arteriosclerosis comprising administering a therapeutically effective amount of a compound of formula (I)
in which
R 1 represents hydrogen or (C1-C4)-alkyl,
where (C1-C4)-alkyl may be substituted by one or two substituents independently of one another selected from the group consisting of fluorine and trifluoromethyl,
or an N-oxide, salt or salt of an N-oxide thereof to a human or animal in need thereof.
50. The method of claim 49 , wherein in the compound of formula (I)
R l represents hydrogen or methyl,
where methyl may be substituted by a trifluoromethyl substituent.
51. The method of claim 49 , wherein the compound of formula (I) is selected from the group consisting of:
methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate
methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}1methylcarbamate
methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}(2,2,2-trifluoroethyl)carbamate
methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate hydrochloride
methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate sulphate
methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate phosphate
methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate mesylate
methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate ethane-1,2-disulphonate
methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate maleate and
methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate nitrate.
52. The method of claim 49 , wherein the compound of formula (I) is:
or an N-oxide, salt, or salt of an N-oxide thereof.
53. The method of claim 49 , wherein the method is for treating or preventing vascular disorders.
54. The method of claim 49 , wherein the method is for treating or preventing thromboembolic disorders.
55. The method of claim 49 , wherein the method is for treating or preventing fibrotic disorders.
56. The method of claim 49 , wherein the method is for treating or preventing arteriosclerosis.
57. The method of claim 49 , wherein the method further comprises administering a further active compound selected from the group consisting of organic nitrates, NO donors, cGMP-PDE inhibitors, agents having antithrombotic activity, agents having blood pressure lowering activity, and agents having lipid metabolism altering activity.
58. The method of claim 57 , wherein the further active compound is an organic nitrate.
59. The method of claim 57 , wherein the further active compound is an NO donor.
60. The method of claim 57 , wherein the further active compound is a cGMP-PDE inhibitor.
61. The method of claim 57 , wherein the further active compound is an agent having antithrombotic activity.
62. The method of claim 57 , wherein the further active compound is an agent having blood pressure lowering activity.
63. The method of claim 57 , wherein the further active compound is an agent having lipid metabolism altering activity.
64. The method of claim 49 , wherein an effective amount of a compound of formula (I-A)
or a salt thereof is administered.
65. The method of claim 64 , wherein an effective amount of the compound of formula (I-A) is administered.
66. The method of claim 64 , wherein an effective amount of the salt of the compound of formula (I-A) is administered.